Onconova Therapeutics Company Profile (NASDAQ:ONTX)

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Symbol: NASDAQ:ONTX
CUSIP: N/A
Web: www.onconova.com

Capitalization:

Market Cap: $13.27 million
Outstanding Shares: 6,772,000

Average Prices:

50 Day Moving Avg: $2.25
200 Day Moving Avg: $2.61
52 Week Range: $1.85 - $8.17

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -0.84
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $5.55 million
Price / Sales: 2.39
Book Value: $0.64 per share
Price / Book: 3.06

Profitability:

EBIDTA: ($20,610,000.00)
Net Margins: -73.67%
Return on Equity: -148.52%
Return on Assets: -50.49%

Debt:

Current Ratio: 3.10%
Quick Ratio: 3.10%

Misc:

Average Volume: 184,124 shs.
Beta: 0.07
Short Ratio: 1.14

Frequently Asked Questions for Onconova Therapeutics (NASDAQ:ONTX)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) posted its earnings results on Monday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.96) by $0.27. The firm had revenue of $0.21 million for the quarter. Onconova Therapeutics had a negative net margin of 73.67% and a negative return on equity of 148.52%. View Onconova Therapeutics' Earnings History.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?

2 brokerages have issued 1 year target prices for Onconova Therapeutics' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.

Who are some of Onconova Therapeutics' key competitors?

Some companies that are related to Onconova Therapeutics include Dimension Therapeutics (DMTX), Marinus Pharmaceuticals (MRNS), Vical Incorporated (VICL), PLx Pharma (PLXP), Cytori Therapeutics (CYTX), Heat Biologics (HTBX), Eleven Biotherapeutics (EBIO), OHR Pharmaceutical (OHRP), OncoSec Medical (ONCS), Auris Medical Holding AG (EARS), Eyegate Pharmaceuticals (EYEG), Galena Biopharma (GALE), Proteon Therapeutics (PRTO), Argos Therapeutics (ARGS), Aviragen Therapeutics (AVIR), Catalyst Biosciences (CBIO), Capricor Therapeutics (CAPR) and CorMedix (CRMD).

Who owns Onconova Therapeutics stock?

Onconova Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tyndall Capital Partners L P (7.69%), Sabby Management LLC (5.68%), Boxer Capital LLC (4.67%), Renaissance Technologies LLC (1.79%) and Vanguard Group Inc. (0.82%). Company insiders that own Onconova Therapeutics stock include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Who sold Onconova Therapeutics stock? Who is selling Onconova Therapeutics stock?

Onconova Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Onconova Therapeutics.

Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?

Onconova Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Boxer Capital LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Onconova Therapeutics stock cost?

One share of Onconova Therapeutics stock can currently be purchased for approximately $1.96.

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$8.00 (308.16% upside)

Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
5/15/2017	Maxim Group	Set Price Target	Buy	$6.00	Low
4/27/2017	Laidlaw	Initiated Coverage	Buy -> Buy	$10.00	Low
3/29/2016	HC Wainwright	Reiterated Rating	Buy		N/A
12/9/2015	Piper Jaffray Companies	Reiterated Rating	Overweight	$60.00	N/A
8/28/2015	Janney Montgomery Scott	Reiterated Rating	Neutral -> Fair Value	$30.00 -> $15.20	N/A

(Data available from 5/27/2015 forward)

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Earnings History by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/15/2017	Q1 2017	($0.96)	($1.23)		$0.21 million	View	N/A
11/14/2016	Q3 2016	($0.82)	($0.29)	$1.60 million	$1.70 million	View	N/A
8/15/2016	Q2		($1.96)		$2.25 million	View	N/A
5/11/2016	Q1	($0.19)	($0.27)	$1.34 million	$1.47 million	View	N/A
3/28/2016	Q4	($0.27)	$0.18		$9.60 million	View	N/A
11/11/2015	Q3	($0.32)	($0.26)	$0.11 million	$1.62 million	View	N/A
8/13/2015	Q2	($0.56)	($0.41)	$0.11 million	$0.12 million	View	N/A
5/14/2015	Q1	($0.63)	($0.57)	$0.11 million	$0.11 million	View	N/A
3/26/2015		($0.71)	($0.62)		$0.11 million	View	N/A
11/13/2014		($0.78)	($0.69)		$0.11 million	View	N/A
8/13/2014		($0.89)	($0.77)	$0.56 million	$0.13 million	View	N/A
5/12/2014		($0.78)	($0.87)	$1.32 million	$0.45 million	View	N/A
3/10/2014	Q4 13	($1.07)	($0.68)	$1.07 million	$1.93 million	View	N/A
11/12/2013	Q3	($0.66)	($1.34)	$1.07 million	$1.12 million	View	Listen
9/6/2013	Q213		($5.21)	$0.22 million	$0.59 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)

Current Year EPS Consensus Estimate: $-3.30 EPS
Next Year EPS Consensus Estimate: $-2.33 EPS

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Onconova Therapeutics (NASDAQ:ONTX)

Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 20.59%

Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/26/2017	E Premkumar Reddy	Director	Buy	119,048	$2.10	$250,000.80
4/26/2017	Mark Patrick Guerin	CFO	Buy	1,429	$2.10	$3,000.90
4/26/2017	Ramesh Kumar	Insider	Buy	23,810	$2.10	$50,001.00
2/21/2014	& Jane Hoffman 2013 De Michael	major shareholder	Buy	143,480	$8.47	$1,215,275.60
2/10/2014	Ramesh Kumar	CEO	Sell	33,543	$15.07	$505,493.01
2/3/2014	Ramesh Kumar	CEO	Sell	60,000	$15.05	$903,000.00
1/27/2014	Michael Hoffman	Director	Buy	57,295	$11.92	$682,956.40
11/22/2013	Michael Hoffman	Director	Buy	5,000	$14.39	$71,950.00
11/18/2013	E Premkumar Reddy	Director	Buy	5,000	$12.10	$60,500.00
11/15/2013	& Jane Hoffman 2013 De Michael	major shareholder	Buy	19,700	$11.99	$236,203.00
11/15/2013	Henry Bienen	Director	Buy	1,400	$12.17	$17,038.00
11/15/2013	Ramesh Kumar	CEO	Buy	1,100	$12.02	$13,222.00
7/30/2013	& Jane Hoffman 2013 De Michael	Major Shareholder	Buy	1,000,000	$15.00	$15,000,000.00
7/30/2013	Ramesh Kumar	CEO	Buy	6,667	$15.00	$100,005.00
7/30/2013	Thomas J Mckearn	Insider	Buy	3,333	$15.00	$49,995.00
7/30/2013	Viren Mehta	Director	Buy	16,667	$15.00	$250,005.00
7/25/2013	E Premkumar Reddy	Director	Buy	1,000	$22.72	$22,720.00

(Data available from 1/1/2013 forward)

Headline Trends for Onconova Therapeutics (NASDAQ:ONTX) Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)

Source:

Date	Headline
	Zacks: Onconova Therapeutics Inc (ONTX) Given Average Recommendation of "" by Analysts www.americanbankingnews.com - May 24 at 4:10 PM
	Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association finance.yahoo.com - May 22 at 9:45 AM
	Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting finance.yahoo.com - May 19 at 11:49 AM
	Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT finance.yahoo.com - May 16 at 6:46 PM
	Onconova Therapeutics Inc (ONTX) Releases Quarterly Earnings Results, Misses Expectations By $0.27 EPS www.americanbankingnews.com - May 16 at 6:14 PM
	Onconova Therapeutics Inc (ONTX) PT Set at $6.00 by Maxim Group www.americanbankingnews.com - May 15 at 3:14 PM
	Investor Network: Onconova Therapeutics Inc. to Host Earnings Call finance.yahoo.com - May 15 at 9:59 AM
	Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results finance.yahoo.com - May 15 at 9:59 AM
	Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results - Nasdaq www.nasdaq.com - May 5 at 7:19 PM
	Onconova Therapeutics Inc (ONTX) Given Average Rating of "Strong Buy" by Brokerages www.americanbankingnews.com - May 5 at 2:28 PM
	Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results finance.yahoo.com - May 4 at 7:13 PM
	Onconova Therapeutics (ONTX) Given Daily Media Sentiment Score of 0.17 www.americanbankingnews.com - May 4 at 11:17 AM
	Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes - Yahoo Finance finance.yahoo.com - May 1 at 12:04 PM
	Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes finance.yahoo.com - May 1 at 12:04 PM
	Bucks County biopharm firm closes $5.2M stock sale www.bizjournals.com - April 29 at 7:28 PM
	Ramesh Kumar Acquires 23,810 Shares of Onconova Therapeutics Inc (ONTX) Stock www.americanbankingnews.com - April 28 at 7:28 PM
	E Premkumar Reddy Purchases 119,048 Shares of Onconova Therapeutics Inc (ONTX) Stock www.americanbankingnews.com - April 28 at 7:27 PM
	Laidlaw Initiates Coverage on Onconova Therapeutics Inc (ONTX) www.americanbankingnews.com - April 27 at 10:12 PM
	Onconova Therapeutics Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release) globenewswire.com - April 27 at 7:30 PM
	Onconova Therapeutics (ONTX) Earning Somewhat Negative Media Coverage, AlphaOne Reports www.americanbankingnews.com - April 27 at 5:04 PM
	Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC finance.yahoo.com - April 26 at 6:14 PM
	Onconova Therapeutics Announces Closing of Public Offering of Common Stock finance.yahoo.com - April 26 at 6:14 PM
	Onconova Therapeutics (ONTX) Receiving Very Favorable Press Coverage, Report Finds www.americanbankingnews.com - April 24 at 9:34 AM
	Onconova Therapeutics (ONTX) Plans Offering of Common Stock www.streetinsider.com - April 22 at 12:28 PM
	Onconova Therapeutics Announces Pricing of Public Offering of Common Stock finance.yahoo.com - April 21 at 6:54 PM
	Onconova Therapeutics stock drops 12% after pricing stock offering finance.yahoo.com - April 21 at 6:54 PM
	Onconova Therapeutics Inc (ONTX) Short Interest Update www.americanbankingnews.com - April 21 at 11:00 AM
	Onconova Therapeutics Announces Proposed Public Offering of Common Stock finance.yahoo.com - April 21 at 12:09 AM
	Onconova Therapeutics (ONTX) Getting Very Positive Press Coverage, Report Finds www.americanbankingnews.com - April 20 at 1:05 PM
	Onconova Therapeutics Inc (ONTX) Receives Average Rating of "Strong Buy" from Brokerages www.americanbankingnews.com - April 20 at 11:19 AM
	Onconova Therapeutics (ONTX) Receives Daily Coverage Optimism Rating of 0.56 www.americanbankingnews.com - April 17 at 12:46 PM
	Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval finance.yahoo.com - April 7 at 11:43 AM
	Analysts Set $5.50 Target Price for Onconova Therapeutics Inc (ONTX) www.americanbankingnews.com - April 5 at 6:30 PM
	Maxim Group Analysts Give Onconova Therapeutics Inc (ONTX) a $6.00 Price Target www.americanbankingnews.com - March 31 at 12:20 PM
	ONCONOVA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report biz.yahoo.com - March 29 at 7:44 PM
	Edited Transcript of ONTX earnings conference call or presentation 27-Mar-17 1:00pm GMT finance.yahoo.com - March 28 at 9:56 AM
	Onconova Therapeutics (ONTX) Falls as Earnings Readied www.baystreet.ca - March 27 at 6:31 PM
	Onconova Therapeutics Inc (ONTX) Given a $6.00 Price Target at Maxim Group www.americanbankingnews.com - March 27 at 3:25 PM
	Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results finance.yahoo.com - March 27 at 9:55 AM
	Q4 2016 Onconova Therapeutics Inc Earnings Release - Before Market Open biz.yahoo.com - March 27 at 9:55 AM
	ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a biz.yahoo.com - March 27 at 9:55 AM
	Onconova Therapeutics Inc (ONTX) Scheduled to Post Quarterly Earnings on Monday www.americanbankingnews.com - March 24 at 9:28 PM
	Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences - GlobeNewswire (press release) globenewswire.com - March 24 at 12:33 AM
	Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences finance.yahoo.com - March 21 at 11:14 AM
	Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results finance.yahoo.com - March 16 at 8:47 AM
	Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March finance.yahoo.com - March 2 at 8:51 AM
	Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February - GlobeNewswire (press release) globenewswire.com - February 10 at 1:10 AM
	Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February finance.yahoo.com - February 9 at 8:08 PM
	Onconova Therapeutics, Inc. to Present at NobleCON13 feeds.benzinga.com - January 27 at 9:34 AM
	SeeThruEquity Initiates Coverage on Onconova Therapeutics, Inc. (NASDAQ: ONTX) with a Price Target of $5.00 finance.yahoo.com - January 12 at 7:40 PM